Abstract
The brain drug development of glial-derived neurotrophic factor (GDNF) is prevented by the lack of transport of this protein across the blood-brain barrier (BBB). GDNF transport across the BBB can be made possible by re-engineering the neurotrophin as a fusion protein with a genetically engineered monoclonal antibody (MAb) against the human insulin receptor (HIR), which crosses the BBB on the endogenous insulin receptor. The present work was designed to compare the BBB transport in vivo of GDNF and the HIR MAb-GDNF fusion protein. Owing to species specificity of HIR MAb binding to the insulin receptor, the present studies were performed in the adult rhesus monkey. The brain uptake of human IgG1 was determined to assess the uptake of a brain plasma volume marker. The brain clearance of GDNF was no different from the clearance of the IgG1, which indicated GDNF does not cross the primate BBB in vivo. In contrast, BBB transport of the HIR MAb-GDNF fusion protein was shown with film and emulsion autoradiography, as well as the capillary depletion method. In parallel with the increased brain uptake, fusion of the GDNF to the HIR MAb resulted in a decrease in the uptake of GDNF by liver, spleen, and kidney. Administration of the HIR MAb-GDNF fusion protein had no effect on glycemic control. The brain uptake parameters show that a systemic dose of the HIR MAb-GDNF fusion protein of 0.2 mg/kg may generate a 10-fold increase in the cerebral concentration of GDNF in the human brain.
Footnotes
-
This work was supported in part by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant R43-NS60176]; and the Michael J. Fox Foundation for Parkinson's Research.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.109.028787
-
- GDNF
- glial-derived neurotrophic factor
- PD
- Parkinson's disease
- BBB
- blood-brain barrier
- CED
- convection-enhanced diffusion
- MAb
- monoclonal antibody
- HIR
- human insulin receptor
- PK
- pharmacokinetics
- hIgG1
- human IgG1
- TCA
- trichloroacetic acid
- VD
- volume of distribution
- ID
- injected dose
- AUC
- area under the plasma concentration curve
- ELISA
- enzyme-linked immunosorbent assay
- ECD
- extracellular domain
- TBS
- Tris-buffered saline
- TBST
- Tris-buffered saline/Tween 20.
- Received June 4, 2009.
- Accepted September 4, 2009.
- Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|